相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- AptarGroup and Massachusetts General Hospital signed a research collaboration to build an integrated translational platform for nose-to-brain drug delivery. - The platform will combine in vitro, in vivo and computational methods to characterize transport mechanisms, pathways and kinetics across molecular classes. - The intended output is a New Approach Methodology (NAM) aligned with FDA support for human-relevant in vitro and in silico drug development tools. - The work is led by Alice Stanton, PhD, and will incorporate Aptar's Cerespray and Neurospray nasal delivery platforms backed by 30 years of field data.
- Aptar Pharma and French biotech Dianosic have formed an exclusive partnership to develop the Active Resorbable Intranasal Scaffold (ARIS) technology platform for treating chronic allergic rhinitis and chronic rhinosinusitis. - The bioresorbable "insert and forget" intranasal delivery system aims to address patient adherence challenges by delivering drugs locally over extended periods. - The collaboration will explore nose-to-brain drug delivery opportunities, particularly for neuropsychiatric and neurodegenerative diseases. - Aptar Pharma will invest in Dianosic and join its strategic committee while promoting the technology to pharmaceutical customers.
